Anti-interleukin-6  tocilizumab  therapy in Takayasu's arteritis: a real life experience

Levent KILIÇ; Ömer KARADAĞ; Abdulsamet ERDEN; Alper SARI; Berkan ARMAĞAN; Gözde Kübra YARDIMCI; Esra Fırat ŞENTÜRK; Umut KALYONCU; Şaziye Şule Apraş BİLGEN; Sedat KİRAZ; Ali İhsan ERTENLİ; Ali AKDOĞAN

doi:https://doi.org/10.3906/sag-1906-39

Makale detayları

Anti-interleukin-6 tocilizumab therapy in Takayasu's arteritis: a real life experience

Yazarlar:

Levent KILIÇ | Ömer KARADAĞ | Abdulsamet ERDEN | Alper SARI | Berkan ARMAĞAN | Gözde Kübra YARDIMCI | Esra Fırat ŞENTÜRK | Umut KALYONCU | Şaziye Şule Apraş BİLGEN | Sedat KİRAZ | Ali İhsan ERTENLİ | Ali AKDOĞAN

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2020 Vol.50 Issue 1, pp.31-36

Belge Tipi:

Makale

Yayın Tarihi:

12/2019

Belge Dili:

İngilizce

Document ID (Org No.):

2000749645

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

DOI:

https://doi.org/10.3906/sag-1906-39

Özet:

 

Background/aim: Tumour  necrosis  factor  inhibitors  and  anti-interleukin-6   anti-IL-6   therapies  are  increasingly  being  used  in  Takayasu's arteritis  TA  patients who are unresponsive to corticosteroids ± conventional immunosuppressive agents.The aim of this study is to assess the efficacy and safety of anti-IL-6  tocilizumab  therapy in refractory TA patients in real life.Materials and methods: Fifteen TA patients  86.7% were female  who received at least 3 cycles of tocilizumab therapy were retrospectively assessed by clinical, laboratory, and radiological evaluations before and after tocilizumab therapy. Results: The median  min-max  age of the patients at evaluation was 35  20-58  years and the median disease duration from diagnosis was 24  12-168  months. The median  min.-max.  duration of follow-up after tocilizumab was 15  3-42  months. There was a significant decrease in erythrocyte sedimentation rate  ESR , C-reactive protein  CRP , and patient global visual analogue scale  VAS  scores of patients after tocilizumab therapy. The median  min.-max.  ESR was 26  5-119  vs. 3  2-49  mm/h, P = 0.02; CRP was 39.8  2.4-149.0  vs. 7.9  0-92.9  mg/L, P = 0.017; and patient global VAS was 50  0-90  vs. 30  0-60 , P = 0.027, respectively. In 8 patients, ESR and CRP levels were in the normal range in the last control. Imaging modality results after tocilizumab were available for 9 patients; 8 patients were radiologically stable and regression was seen in 1 patient. Comparable imaging modality results before and after tocilizumab were available for 5 patients; 4 patients were radiologically stable and regression was seen in 1 patient. Radiological findings were consistent with laboratory responses. Glucocorticoid dosages decreased from a mean dosage of 16.2  9.1  mg/day at baseline to 7.1  3.8  mg/day  P = 0.001  at the last follow-up visit. There was no increase in the steroid dosage in any of the patients. All patients tolerated tocilizumab well. Conclusion: Based on retrospective real life data, anti-IL-6  tocilizumab  appears to be an effective and tolerable treatment option in refractory TA patients.

Makale detayları

Anti-interleukin-6 tocilizumab therapy in Takayasu's arteritis: a real life experience

Yazarlar: Levent KILIÇ | Ömer KARADAĞ | Abdulsamet ERDEN | Alper SARI | Berkan ARMAĞAN | Gözde Kübra YARDIMCI | Esra Fırat ŞENTÜRK | Umut KALYONCU | Şaziye Şule Apraş BİLGEN | Sedat KİRAZ | Ali İhsan ERTENLİ | Ali AKDOĞAN

Yayıncı: TUBITAK

Dergi: Turkish Journal of Medical Sciences 2020 Vol.50 Issue 1, pp.31-36

Belge Tipi: Makale

Yayın Tarihi: 12/2019

Belge Dili: İngilizce

Document ID (Org No.): 2000749645

Sıklık: İki Aylık

eISSN: 1303-6165

pISSN: 1300-0144

DOI: https://doi.org/10.3906/sag-1906-39

Sayı

Yazarlar:

Levent KILIÇ | Ömer KARADAĞ | Abdulsamet ERDEN | Alper SARI | Berkan ARMAĞAN | Gözde Kübra YARDIMCI | Esra Fırat ŞENTÜRK | Umut KALYONCU | Şaziye Şule Apraş BİLGEN | Sedat KİRAZ | Ali İhsan ERTENLİ | Ali AKDOĞAN

Yayıncı:

TUBITAK

Dergi:

Turkish Journal of Medical Sciences 2020 Vol.50 Issue 1, pp.31-36

Belge Tipi:

Makale

Yayın Tarihi:

12/2019

Belge Dili:

İngilizce

Document ID (Org No.):

2000749645

Sıklık:

İki Aylık

eISSN:

1303-6165

pISSN:

1300-0144

DOI:

https://doi.org/10.3906/sag-1906-39